Physician profile
Darren E Killen
NPI 1114920295
$4,502.74
in general payments reported to CMS, 2019-2025
40 companies · $907 in 2025
The $907 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $320 · 2021: $608 · 2022: $502 · 2023: $754 · 2024: $977 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,638.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $719.73 | 2021-2025 | |
| Lilly USA, LLC | $501.03 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Viiv Healthcare Company | $474.42 | 2022-2025 | Apretude |
| Novo Nordisk INC | $407.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $245.95 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.82 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $216.21 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $201.78 | 2019-2021 | |
| Amgen INC. | $160.48 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $157.67 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.20 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $116.81 | 2019-2025 | |
| Corium, LLC | $115.33 | 2023-2024 | Azstarys |
| Novartis Pharmaceuticals Corporation | $100.53 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $84.72 | 2020-2024 | Livalo |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Killen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.